Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023

Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) announced plans to report its fourth quarter and full year 2022 financial results on February 28, 2023. The company will also provide a business update during the conference call scheduled for 8:30 AM ET that day. The call will be accessible via their Investor Relations website. Altimmune focuses on developing novel peptide-based therapeutics for obesity and liver diseases, with its lead candidate, pemvidutide (ALT-801), targeting obesity and NASH. Additionally, the company is working on HepTcell™, aimed at chronic hepatitis B treatment.

Positive

• Altimmune's lead product, pemvidutide (ALT-801), is a dual receptor agonist that targets obesity and NASH.
• The upcoming financial results announcement may provide insights into the company's growth trajectory.

Negative

• None.

GAITHERSBURG, Md., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 and will provide a business update.

Altimmune management will host a conference call at 8:30 am E.T. on February 28 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.

Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to twelve months.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor and Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com

FAQ

What are Altimmune's fourth quarter and full year 2022 financial results release date?

Altimmune will report its financial results on February 28, 2023.

What time is the Altimmune conference call for financial results?

The conference call is scheduled for 8:30 AM ET on February 28, 2023.

How can I access the Altimmune conference call?

The conference call can be accessed through Altimmune's Investor Relations website.

What is Altimmune's lead product candidate?

Altimmune's lead product candidate is pemvidutide (ALT-801), aimed at treating obesity and NASH.

What additional therapeutics is Altimmune developing?

Altimmune is also developing HepTcell™, designed for chronic hepatitis B treatment.